Form 4: Apellis Pharmaceuticals Acquired by Biogen

Director Mikael Dolsten reports the disposition of all Apellis Pharmaceuticals equity holdings following the company's acquisition by Biogen.

Summary

• Apellis Pharmaceuticals, Inc. has been acquired by Biogen Inc. via a merger agreement dated March 31, 2026.
• The acquisition was finalized on May 14, 2026, with Apellis becoming a wholly owned subsidiary of Biogen.
• Shareholders received $41.00 per share in cash plus one contingent value right (CVR) per share.
• The CVR entitles holders to potential additional payments of up to $4.00 upon the achievement of specific milestones.
• Reporting person Mikael Dolsten disposed of 14,312 shares of common stock and 24,135 stock options as part of the merger consideration.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, as the acquisition provides immediate liquidity at a premium and potential future upside through CVRs.

Positives

• Shareholders received a definitive cash consideration of $41.00 per share.
• The inclusion of a CVR provides potential upside of up to $4.00 per share based on future milestones.
• The transaction represents a successful exit for shareholders through a strategic acquisition by a major industry player.

Negatives

• The company is no longer a publicly traded entity following the merger.
• Future potential value is contingent upon specific milestones defined in the CVR agreement.

Risks

• The $4.00 per share CVR value is not guaranteed and depends on the achievement of specific, undisclosed milestones.
• The CVR is non-transferable, limiting liquidity for former shareholders regarding this portion of the consideration.

Future Outlook

Apellis Pharmaceuticals is now a wholly owned subsidiary of Biogen, and its future performance will be integrated into Biogen's corporate strategy.

Management Comments

• The transaction was executed pursuant to the Agreement and Plan of Merger dated March 31, 2026.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of large-cap biopharmaceutical companies acquiring mid-cap innovators to bolster their pipelines, particularly in specialized therapeutic areas.

Comparison to Industry Standards

• The use of CVRs in this acquisition is consistent with recent industry trends in biotech M&A to bridge valuation gaps between buyers and sellers regarding pipeline assets.
• The $41.00 cash offer represents a standard premium-based exit for shareholders in the current biopharma M&A environment.

Stakeholder Impact

• Shareholders have received cash consideration for their equity.
• Employees and operations are now under the governance of Biogen.

Next Steps

• Integration of Apellis Pharmaceuticals into Biogen operations.
• Monitoring of milestones related to the CVR agreement for potential future payouts.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, Contingent Value Right, CVR, Form 4